Leurocristine
Brand names,
Leurocristine
Analogs
Leurocristine
Brand Names Mixture
Leurocristine
Chemical_Formula
C46H56N4O10
Leurocristine
RX_link
http://www.rxlist.com/cgi/generic3/vincristine.htm
Leurocristine
fda sheet
Leurocristine
msds (material safety sheet)
Leurocristine
Synthesis Reference
No information avaliable
Leurocristine
Molecular Weight
824.958 g/mol
Leurocristine
Melting Point
220 oC
Leurocristine
H2O Solubility
No information avaliable
Leurocristine
State
Solid
Leurocristine
LogP
4.918
Leurocristine
Dosage Forms
Liquid; Solution
Leurocristine
Indication
For treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, acute panmyelosis
Leurocristine
Pharmacology
Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.
Leurocristine
Absorption
No information avaliable
Leurocristine
side effects and Toxicity
IVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg
Leurocristine
Patient Information
PATIENT INFORMATION
Follow the links
http://www.rxlist.com/cgi/generic3/vincristine_wcp.htm
http://www.drugs.com/cons/Vincristine.html
Leurocristine
Organisms Affected
Humans and other mammals